The Path of Yeast Resistance: Drug-resistant Candida on the Rise | COCA

Written by

admin

in

Overview

Candida is a yeast that can cause infections ranging in severity. Antifungal resistance among Candida is growing, particularly for specific species such as Candida auris and Candida parapsilosis. These two species also spread more easily between patients in healthcare settings compared to other species of Candida. Awareness of this issue is essential for clinicians, as it can guide testing practices and clinical treatment decisions.

During this COCA Call, presenters will share current evidence demonstrating the increase in antifungal resistance among C. auris and C. parapsilosis and discuss recommendations for testing and treatment.

Webinar

Date: Thursday, September 18, 2025

Time: 2:00-3:00 P.M. ET

A few minutes before the webinar begins, please click here to join.

Presenters

Dallas Smith, PharmD, MAS
Epidemiologist
Mycotic Diseases Branch
Division of Foodborne Waterborne, and Environmental Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Meghan Lyman, MD
Acting Deputy Branch Chief
Mycotic Diseases Branch
Division of Foodborne Waterborne, and Environmental Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, populations at higher risk, and other members of an interprofessional team of healthcare providers.

Activity-specific Objectives

  1. Describe the increasing prevalence of resistant Candida species.
  2. Explain the epidemiology of emerging resistant Candida.
  3. Outline appropriate testing including species identification, antifungal susceptibility testing, and whole genome sequencing.
  4. Summarize treatment options and resources for resistant Candida species.

Continuing Education

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for WC4520R-091825—The Path of Yeast Resistance: Drug-resistant Candida on the Rise, please visit CDC TRAIN

To receive continuing education (CE) for WD4520R-091825—The Path of Yeast Resistance: Drug-resistant Candida on the Rise, please visit CDC TRAIN

  1. Register for and complete the course.
  2. Pass the post-assessment at 75%.
  3. Complete the evaluation.
  4. Visit Your Learning to access your certificates and transcript.

Accreditation Statements

CDC is a Jointly Accredited Provider of Interprofessional Continuing Education.

CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-25-050-L04-P and enduring JA4008229-0000-25-051-H04-P.

CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: Credit Designation Statement – Live The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEUs for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Meghan Lyman’s discussion of several antifungal medications in clinical trials for C. auris and availability of use under expanded access programs.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

CDC complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex. To learn more visit: https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html

Continue Reading

More posts